25.01.2013 Views

Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

132 7 Immunosuppresive Factors in <strong>Cancer</strong><br />

strated the role of PGE2 in suppressing polyclonal T cell activation <strong>and</strong> CTL generation<br />

following MLRs <strong>by</strong> splenic T cells [233]. PGE2 treatment of stimulated peripheral<br />

blood lymphocytes <strong>and</strong> CD4 + T cells decreases IL-2 <strong>and</strong> IFN-g production <strong>and</strong> promotes<br />

IL-10 production [234, 235]. However, CD8 + T cell effector functions are reported to<br />

be more sensitive to the suppressive effects of PGE2 than CD4 + T cells [236]. PGE2<br />

inhibits T cell migration [237], promotes T cell anergy [238], <strong>and</strong> suppresses CD8 +<br />

CTL activity in vitro <strong>and</strong> in vivo [239±242].<br />

7.4.2.3 Effects of PGE2 on NK cells <strong>and</strong> LAK activity<br />

Similar to its immunosuppressive effects on CTLs, PGE2 has been reported to inhibit<br />

NK activity [233, 243±246] <strong>and</strong> LAK cell activity [233]. These findings correlate with reports<br />

that NK activity inversely correlates with monocyte-derived PGE2 levels, <strong>and</strong><br />

that removal of monocytes from the PBMCs of patients with breast cancer restored<br />

NK <strong>and</strong> LAK levels when compared to healthy controls [247].<br />

7.4.3<br />

Inhibition of PGE2: Implications for <strong>Therapy</strong><br />

Slowed tumor growth <strong>and</strong> the inhibition of metastases has been observed <strong>by</strong> in vivo<br />

blockade of PGE2 activity using PGE2 immunization [248], anti-PGE2 antibodies<br />

[249] <strong>and</strong> inhibition of PGE2 production using COX inhibitors [244, 250±254]. Inhibition<br />

of COX-2 (<strong>and</strong> thus PGE2 production) in an experimental tumor model using<br />

the Lewis lung carcinoma cell line results in a significant decrease in IL-10 production<br />

together with a significant increase in IL-12 secretion, thus restoring host antitumor<br />

reactivity [253]. Similar findings have been observed in COX knockout mice<br />

[255, 256].<br />

The precise mechanisms <strong>by</strong> which COX inhibitors slow tumor growth are not well<br />

understood. A very recent study <strong>by</strong> Specht et al. revealed that COX inhibitors enhance<br />

the host CTL responses in an experimental tumor model [252]. More interestingly,<br />

human epidemiological studies suggest the antineoplastic activities of COX inhibitors<br />

[257±259]. However, COX inhibitors also have been associated with the inhibition<br />

of angiogenesis (reviewed in [260]) <strong>and</strong> tumor growth <strong>and</strong> telomerase elongation<br />

activity in tumor cells [254].<br />

7.5<br />

Polyamines<br />

Polyamines (putrecine, spermine <strong>and</strong> spermadine) are natural occurring small organic<br />

cations. Polyamines are critical for both cell proliferation <strong>and</strong> differentiation<br />

(reviewed in [261]). Much of our knowledge of polyamine bioactivity stems from the<br />

use of inhibitors of polyamine biosynthesis (see below).

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!